Bionano Genomics, Inc. (BNGO) financial statements (2021 and earlier)

Company profile

Business Address 9540 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments381717
Cash and cash equivalents381717
Receivables365
Inventory, net of allowances, customer advances and progress billings331
Inventory331
Prepaid expense211
Other current assets000
Total current assets:472823
Noncurrent Assets
Property, plant and equipment522
Intangible assets, net (including goodwill)9  
Goodwill7  
Intangible assets, net (excluding goodwill)1  
Other noncurrent assets0  
Total noncurrent assets:1422
TOTAL ASSETS:603025
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities964
Accounts payable331
Accrued liabilities633
Deferred revenue00
Debt 20 
Other undisclosed current liabilities  0
Total current liabilities:9265
Noncurrent Liabilities
Long-term debt and lease obligation16 9
Long-term debt, excluding current maturities16 9
Liabilities, other than long-term debt001
Deferred revenue00
Other liabilities 01
Other undisclosed noncurrent liabilities  0
Total noncurrent liabilities:16010
Total liabilities:252715
Stockholders' equity
Stockholders' equity attributable to parent35410
Common stock000
Additional paid in capital17910683
Accumulated deficit(144)(103)(73)
Total stockholders' equity:35410
TOTAL LIABILITIES AND EQUITY:603025

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Revenues91012
Cost of revenue
(Cost of Goods and Services Sold)
(6)(7)(9)
Gross profit:333
Operating expenses(41)(29)(24)
Operating loss:(39)(26)(20)
Nonoperating income (expense)(3)(4)2
Other nonoperating expense(0)(0)(1)
Interest and debt expense(3)(1)(0)
Loss from continuing operations before equity method investments, income taxes:(44)(31)(19)
Other undisclosed income from continuing operations before income taxes310
Loss from continuing operations before income taxes:(41)(30)(18)
Income tax expense(0)(0)(0)
Net loss available to common stockholders, diluted:(41)(30)(18)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(41)(30)(18)
Comprehensive loss, net of tax, attributable to parent:(41)(30)(18)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: